CRIS Current Research Information System

CALZA, LEONARDO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.219
EU - Europa 8.613
AS - Asia 4.133
AF - Africa 475
SA - Sud America 30
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 4
Totale 23.484
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.201
GB - Regno Unito 2.785
CN - Cina 1.664
DE - Germania 1.211
UA - Ucraina 1.067
IT - Italia 1.065
SG - Singapore 1.053
SE - Svezia 966
VN - Vietnam 728
IN - India 507
RU - Federazione Russa 410
FR - Francia 377
IE - Irlanda 332
ZA - Sudafrica 199
EE - Estonia 175
TG - Togo 119
SC - Seychelles 91
JP - Giappone 75
BG - Bulgaria 53
FI - Finlandia 42
JO - Giordania 39
CI - Costa d'Avorio 36
CH - Svizzera 35
NG - Nigeria 24
GR - Grecia 22
LB - Libano 20
BE - Belgio 18
NL - Olanda 17
BR - Brasile 12
ID - Indonesia 11
AU - Australia 10
CA - Canada 10
CL - Cile 10
ES - Italia 7
MX - Messico 7
TR - Turchia 7
UZ - Uzbekistan 7
IR - Iran 6
RO - Romania 6
AT - Austria 5
PH - Filippine 5
PT - Portogallo 5
EU - Europa 4
LT - Lituania 4
AR - Argentina 3
CZ - Repubblica Ceca 3
HK - Hong Kong 3
MA - Marocco 3
SA - Arabia Saudita 3
VE - Venezuela 3
BO - Bolivia 2
ET - Etiopia 2
HR - Croazia 2
PL - Polonia 2
SK - Slovacchia (Repubblica Slovacca) 2
AE - Emirati Arabi Uniti 1
EG - Egitto 1
KW - Kuwait 1
KZ - Kazakistan 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MS - Montserrat 1
NO - Norvegia 1
PK - Pakistan 1
Totale 23.484
Salva come PNG Salva come JPEG
Città #
Southend 2.518
Fairfield 1.168
Singapore 926
Jacksonville 771
Ashburn 762
Chandler 707
Wilmington 614
Woodbridge 579
Santa Clara 571
Princeton 556
Seattle 501
Houston 460
Dong Ket 417
Cambridge 395
Dublin 332
Ann Arbor 331
Boardman 312
Nanjing 272
Westminster 255
Padova 241
Bologna 232
Berlin 201
Saint Petersburg 130
Mülheim 126
Jinan 121
Lomé 119
Shenyang 108
San Diego 94
Mahé 90
Medford 90
Milan 88
Beijing 85
Nanchang 85
Hebei 81
Changsha 70
Tokyo 68
Tianjin 56
Dearborn 54
Sofia 53
Florence 52
Verona 52
Jiaxing 50
Zhengzhou 44
Norwalk 42
Guangzhou 41
Falls Church 40
Helsinki 40
Olalla 40
Amman 39
Des Moines 39
Hangzhou 38
Ningbo 37
Turin 37
Abidjan 36
New York 36
Redmond 36
Los Angeles 35
Kunming 34
Shanghai 32
Lanzhou 31
Haikou 26
Abeokuta 24
Bühl 23
Brussels 18
Taizhou 18
Bremen 17
Hefei 17
Rome 17
Wuhan 17
Bern 16
London 14
Phoenix 14
Redwood City 14
Taiyuan 14
Xi'an 14
Qingdao 13
Shenzhen 13
Foshan 11
Frankfurt Am Main 11
Fuzhou 11
San Venanzo 11
Chicago 10
Wenzhou 10
Jakarta 9
Paris 9
Shijiazhuang 9
Costa Mesa 7
Moscow 7
Muizenberg 7
Plauen 7
San Jose 7
Amsterdam 6
Anzola Dell'emilia 6
Istanbul 6
Kiev 6
Mountain View 6
Pune 6
San Francisco 6
Toronto 6
Washington 6
Totale 15.939
Salva come PNG Salva come JPEG
Nome #
Acute onset myopericarditis as unusual presentation of primary HIV infection 198
Assessing the impact of hepatitis C virus coinfection on lopinavir/ritonavir trough concentrations in HIV-infected patients. 177
Comparison of the Aptima HIV-1 Quant Dx Assay with the COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 v2.0 Test for HIV-1 Viral Load Quantification in Plasma Samples from HIV-1-Infected Patients. 171
Cardiovascular risk factors and ultrasound evaluation of carotid atherosclerosis in patients with HIV-1 infection. 155
Development of C-TILDA: A modified TILDA method for reservoir quantification in long term treated patients infected with subtype C HIV-1 152
A 2-year survey of bacteriologic profile and antimicrobial susceptibility levels of Enterococci in a large Italian teaching hospital. 151
Abacavir-induced febrile agranulocytosis and anaemia. 149
Ultrastructural liver mitochondrial abnormalities in HIV/HCV-coinfected patients receiving antiretroviral therapy 147
A decade surveillance study of Mycobacterium xenopi disease and antimicrobial susceptibility levels in a reference teaching hospital of northern Italy: HIV-associated versus non-HIV-associated infection. 146
Myocardial infarction risk in HIV-infected patients: epidemiology, pathogenesis, and clinical management 143
Atypical progressive multifocal leukoencephalopathy in HIV with a high CD4 count: the use of magnetic resonance imaging plus spectrometry studies 143
Significant Decrease in Plasma Levels of D-Dimer, Interleukin-8, and Interleukin-12 After a 12-Month Treatment with Rosuvastatin in HIV-Infected Patients Under Antiretroviral Therapy 141
Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia. 140
Increasing pathomorphism of pulmonary tuberculosis: an observational study of slow clinical, microbiological, and imaging response of lung tuberculosis to specific treatment. Which role for linezolid? 137
Changes in Serum Markers of Inflammation and Endothelial Activation in HIV-Infected Antiretroviral Naive Patients Starting A Treatment with Abacavir-Lamivudine or Tenofovir-Emtricitabine Plus Efavirenz 136
Severe peripheral neuropathy with areflexic and flaccid quadriplegia complicating Legionnaires’ disease in an adult patient. 134
Calcaneal quantitative ultrasound (QUS) and dual X-ray absorptiometry (DXA) bone analysis in adult HIV-positive patients. 133
A prospective evaluation of maraviroc administration in patients with advanced HIV disease and multiple comorbidities: focus on efficacy and tolerability issues 132
Prevalence of renal disease within an urban HIV-infected cohort in northern Italy. 131
Dual raltegravir-darunavir/ritonavir combination in virologically suppressed HIV-1-infected patients on antiretroviral therapy including a ritonavir-boosted protease inhibitor plus two nucleoside/nucleotide reverse transcriptase inhibitors 131
Protease inhibitor monotherapy as maintenance regimen in patients with HIV infection. 130
Plasma Levels of VCAM-1, ICAM-1, E-Selectin, and P-Selectin in 99 HIV-positive patients versus 51 HIV-negative healthy controls. 128
Skeletal muscle toxicity in HIV-1-infected patients treated with a raltegravir-containing antiretroviral therapy: a cohort study. 127
Prevalence of R5 strains in multi-treated HIV subjects and impact of new regimens including maraviroc in a selected group of patients with CCR5-tropic HIV-1 infection. 126
Amiodarone-related pneumonitis and peripheral neuropathy in an elderly patient 126
Chronic hepatitis with diffuse steatosis and slight fibrosis related to etretinate therapy 123
Pancreotoxicity of propofol sedation during purulent meningitis. 123
Prevalence And Mutational Pattern Of Occult Hepatitis B Virus Isolated From Liver Tissue Of HIV Infected Patients 122
Human immunodeficiency virus and hepatitis C virus coinfection: epidemiology, natural history, therapeutic options and clinical management 121
Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice 121
Plasma trough concentrations of darunavir/ritonavir and raltegravir in older patients with HIV-1 infection. 121
Bladder carcinoma and HIV infection during the highly active antiretroviral therapy era: a rare, but intriguing association. Two case reports and literature review 121
Multiplexed therapeutic drug monitoring (TDM) of antiviral drugs by LC–MS/MS 120
A prognostic model for estimating the time to virologic failure in HIV-1 infected patients undergoing a new combination antiretroviral therapy regimen 119
Impact of different antiretroviral strategies on total HIV-DNA level in virologically suppressed HIV-1 infected patients. 119
Molecular Bases of Osteoporosis in HIV: The Role of the Virus and Antiretroviral Therapy 119
Outcome of hepatocellular carcinoma in human immunodeficiency virus-infected patients. 118
A prospective comparison of hepatotoxicity of the two currently available non-nucleoside reverse transcriptase inhibitors in a homogeneous case-mix of HIV-infected patients treated for the first time with efavirenz or nevirapine, according to their different baseline conditions 117
Insulin resistance and diabetes mellitus in HIV-infected patients receiving antiretroviral therapy 117
Aderenza alla terapia antiretrovirale "autogestita" dai pazienti alla metà della posologia giornaliera raccomandata. Inattesa efficacia immunologica e virologica a lungo termine 116
Epidemiological, clinical and therapeutic features of AIDS-related Mycobacterium kansasii infection during the HIV pandemic: an 11-year follow-up study. 116
Two-Year Treatment with Rosuvastatin Reduces Carotid Intima-Media Thickness in HIV Type 1-Infected Patients Receiving Highly Active Antiretroviral Therapy with Asymptomatic Atherosclerosis and Moderate Cardiovascular Risk. 115
Abacavir-lamivudina versus tenofovir-emtricitabina più atazanavir-ritonavir nella semplificazione dell'HAART per dislipidemia 115
Lopinavir/ritonavir trough concentrations with the tablet formulation in HIV-1-infected women during the third trimester of pregnancy. 115
Incidence of renal toxicity in HIV-infected, antiretroviral-naïve patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavir 114
No correlation between statin exposure and incident diabetes mellitus in HIV-1-infected patients receiving combination antiretroviral therapy 114
Risk of premature atherosclerosis and ischemic heart disease associated with HIV infection and antiretroviral therapy 113
null 113
HIV and kidney: A dangerous liaison 113
Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weighting. 112
Plasma concentrations of efavirenz, darunavir/ritonavir and raltegravir in HIV-HCV-coinfected patients without liver cirrhosis in comparison with HIV-monoinfected patients. 112
Bone mass loss in patients with human immunodeficiency virus type 1 infection: association with male sex and protease inhibitor therapy 111
Changing epidemiology of hepatitis A in the Bologna metropolitan area, northern Italy: importance of counselling and prophylactic measures for the male homo/bisexual population. 111
HIV-1 early and late diagnosis in the Emilia Romagna Region (Italy): A three year study 111
Chron’s disease, rare association with selective IgA immunodeficiency, and development of life-threatening bacterial infections. 111
Stabilizzazione a lungo termine dell'assetto virologico e immunologico dell'infezione da HIV in un "AIDS Presenter" seguito per oltre vent'anni, nonostante la mancata aderenza alla terapia antiretrovirale 110
Disseminated cutaneous leishmaniasis after visceral disease in a patient with AIDS 110
Improvement in insulin sensitivity and serum leptin concentration after the switch from a ritonavir-boosted PI to raltegravir or dolutegravir in non-diabetic HIV-infected patients 110
Prospective, open-label comparative study of liver toxicity in an unselected population of HIV-infected patients treated for the first time with efavirenz or nevirapine 109
Gynecomastia, lipodystrophy syndrome, and dyslipidemia occurring or worsening during antiretroviral regimens other than protease inhibitor-based ones. 108
Rosuvastatin for the treatment of hyperlipidaemia in HIV-infected patients receiving protease inhibitors: a pilot study. 108
An observational study of subcutaneous multiple lipomatosis in patients receiving highly active antiretroviral therapy. Possible correlations with metabolic abnormalities and pathogenetic insights 108
Safety issues about nevirapine administration in HIV-infected pregnant women 107
AIDS-associated atypical mycobacteriosis other than Mycobacterium avium-intracellulare: a 15-year survey of Mycobacterium kansasii and Mycobacterium xenopi 107
HIV-1 coreceptor usage in paired plasma RNA and proviral DNA from patients with acute and chronic infection never treated with antiretroviral therapy 107
Cardiovascular prevention in HIV-positive individuals on antiretroviral therapy.. The paradigm shift has already happened: Is it time to wake up and realise it? 107
Improvement in liver steatosis after the switch from a ritonavir-boosted protease inhibitor to raltegravir in HIV-infected patients with non-alcoholic fatty liver disease. 107
Primary Cytomegalovirus infection in otherwise healthy adults with Fever of Unknown Origin: a 3-year prospective survey 106
Statin therapy decreases serum levels of high-sensitivity C-reactive protein and tumor necrosis factor-alpha in HIV-infected patients treated with ritonavir-boosted protease inhibitors. 106
Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study. 105
Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients. 105
Tenofovir/emtricitabine/efavirenz plus rosuvastatin decrease serum levels of inflammatory markers more than antiretroviral drugs alone in antiretroviral therapy-naive HIV-infected patients. 105
Measles outbreak in the city of Bologna, December 2007 to May 2008 104
Severe pneumococcal meningitis heralding a deep hypogammaglobulinaemia related to common variable immunodeficiency, at the age of 27 years. 104
Legionnaires' disease associated with macular rash: two cases 103
Adenocarcinoma vescicale in corso di infezione da HIV. Percorso diagnostico, clinico e terapeutico di tre casi clinici 103
An extremely different dysmetabolic profile between the two available nonucleoside reverse transcriptase inhibitors: efavirenz and nevirapine. 102
First-line efavirenz versus lopinavir/ritonavir-based highly active antiretroviral therapy for naïve patients. 102
Efficacy and tolerability of a fosamprenavir-ritonavir-based versus a lopinavir-ritonavir-based antiretroviral treatment in 82 therapy-naïve patients with HIV-1 infection. 102
Extra-western European citizens in the setting of infectious diseases: a rapidly evolving trend in northern Italy. 102
Antiretroviral therapy voluntarily taken at half-dosage, but fully effective after 6-10 years: a provocative issue for adherence requirements. Case report 102
COVID-19 in patients with HIV-1 infection: a single-centre experience in northern Italy 102
AIDS e patologie tumorali multiple come condizioni emergenti in epoca di terapia antiretrovirale altamente attiva (HAART) 102
Hyperlactataemia and lactic acidosis in HIV-infected patients receiving antiretroviral therapy. 101
Severe brain co-infection with Cryptococcus neoformans and Mycobacterium tuberculosis in a young, otherwise healthy student recently immigrated from China 100
Tenofovir-induced renal toxicity in 324 HIV-infected, antiretroviral-naive patients. 100
Diffuse cutaneous dissemination of visceral leishmaniasis during human immunodeficiency virus (HIV) infection, despite negligible immunodeficiency: repeated failure of liposomal amphotericin B administration, followed by successful long-term pentamidine and paromomycin administration 100
Prevalence, awareness, treatment, and control rate of hypertension in HIV-infected patients: the HIV-HY study 100
Renal toxicity associated with antiretroviral therapy 100
Membranoproliferative glomerulonephritis associated with human immunodeficiency virus, hepatitis B and hepatitis C virus coinfection: case report and literature review. 99
Polyunsaturated ethyl esters on n-3 fatty acids in HIV-infected patients with moderate hypertriglyceridemia: comparison with dietary and lifestyle changes, and fibrate therapy. 99
Methicillin-resistant staphylococci still susceptible to non-beta-lactam antibiotics. What clinical implications in nosocomially-acquired infections? 99
Antibiotic therapy for infective endocarditis in childhood 99
Human herpesvirus-8-related Kaposi’s sarcoma after liver transplantation successfully treated with cidofovir and liposomal daunorubicin. 99
A case-control study of HIV-associated pancreatic abnormalities during HAART era. Focus on emerging risk factors and specific management. 99
Factors associated with vitamin D deficiency in HIV-1 infected patients on combination antiretroviral therapy: a case-control study. 99
HIV infection and the pancreas: risk factors and potential management guidelines 98
Rosuvastatin and atorvastatin preserve renal function in HIV-1-infected patients with chronic kidney disease and hyperlipidaemia 98
Prevalence of chronic kidney disease among HIV-1-infected patients receiving a combination antiretroviral therapy 98
Antiretroviral treatment and gynecomastia: which correlations? 97
Totale 11.715
Salva come PNG Salva come JPEG
Categoria #
all - tutte 61.148
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 61.148
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20203.648 0 0 0 0 0 545 666 834 636 395 131 441
2020/20213.305 834 284 65 175 45 194 40 209 198 231 177 853
2021/20224.312 402 215 284 406 405 262 77 331 146 349 732 703
2022/20233.746 467 596 209 473 237 225 127 188 621 118 361 124
2023/2024867 72 156 63 98 66 158 51 62 25 64 23 29
2024/20252.958 118 901 407 359 976 197 0 0 0 0 0 0
Totale 23.904